ABEO Historical PE Ratio Notes

— Abeona Therapeutics (“ABEO”) is a clinical-stage biopharmaceutical company focused on developing gene & cell therapies for rare genetic diseases, particularly those with limited or no existing treatments. Its pipeline is anchored by EB-101, a gene therapy for recessive dystrophic epidermolysis bullosa, and ABO-102, targeting Sanfilippo syndrome type A. Because Abeona is pre-commercial and has not yet generated meaningful revenue from product sales, its historical earnings have been negative or minimal over past years. This significantly impacts historical price-to-earnings (P/E) ratios: in many periods, ABEO will not have a calculable P/E ratio (since earnings are negative or near zero), or, when earnings are reported, the ratio may appear very high or highly volatile due to small denominators. Investors looking at ABEO charts and tables will notice stretches with no meaningful P/E, reflecting the company's R&D-focused spending phase and absence of profitability. In summary, ABEO's business model & stage of development mean its historical P/E ratio is not a typical valuation yardstick as it would be for profitable firms, but it does highlight the speculative nature and future-oriented expectations often factored into the stock price by the market.

On this page we presented the ABEO Historical PE Ratio information for Abeona Therapeutics' stock. The average ABEO historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 0.5. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average ABEO historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this ABEO historical PE result, against the recent PE: when this page was posted on 8/6/2026, the most recent closing price for ABEO had been 6.90, and the most recent quarterly earnings result, annualized, was 6.08. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent ABEO PE on 8/6/2026 based on annualized quarterly EPS was 1.1. Based on ABEO's history, that recent PE is elevated relative to the historical average, with the recent PE 120.0% higher than the historical average PE across our data set for Abeona Therapeutics.

For self directed investors doing their due diligence on ABEO or any other given stock, valuation analysis for ABEO can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Abeona Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for ABEO. Thanks for visiting, and the next time you need to research ABEO Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.